Keryx Biopharmaceuticals (KERX) Announces FDA Acceptance for Filing of Zerenex New Drug Application
10/8/2013 9:53:29 AM
NEW YORK, Oct. 8, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that its New Drug Application (NDA) for Zerenex™ (ferric citrate coordination complex) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance for filing of the NDA indicates the determination by the FDA that the application is sufficiently complete to permit a substantive review.
Help employers find you! Check out all the jobs and post your resume.
comments powered by